Target- |
Mechanism- |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
This trial will study REPEL-CV for reducing post operative adhesions following cardiovascular (cv) surgery.
100 Clinical Results associated with SyntheMed, Inc.
0 Patents (Medical) associated with SyntheMed, Inc.
100 Deals associated with SyntheMed, Inc.
100 Translational Medicine associated with SyntheMed, Inc.